Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New daily pill aims to beat standard diabetes drug in blood sugar battle

NCT ID NCT06192108

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new once-daily pill called orforglipron against an existing drug, dapagliflozin, in adults with type 2 diabetes whose blood sugar was not well controlled with metformin alone. About 962 participants took either orforglipron or dapagliflozin for roughly 46 weeks. The main goal was to see which pill better lowered blood sugar levels (HbA1c) and helped with weight loss.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

962 people

The number who actually took part.

Started

Jan 2024

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have a clinical diagnosis of T2D based on the World Health Organization classification or other locally applicable diagnostic standards. * Have HbA1c ≥7.0% (53 mmol/mol) to ≤10.5% (91 mmol/mol) at screening. * Have been on stable diabetes treatment with metformin ≥1500 milligram per day (mg/day) during the 90 days prior to screening and maintained through randomization. * Are of stable body weight (±5%) for at least 90 days prior to screening and agree to not initiate an intensive diet or exercise program during the study with the intent of reducing body weight, other than the lifestyle and/or dietary measures for diabetes treatment. * Have a body mass index (BMI) ≥23.0 kilogram/square meter (kg/m²) at screening. Exclusion Criteria: * Have Type 1 Diabetes (T1D) * Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema * Have an estimated glomerular filtration rate (eGFR) \<45 milliliter per minute (mL/min)/1.73 square meter (m2) * Have acute or chronic hepatitis * Have had chronic or acute pancreatitis any time. * Have been treated with any antihyperglycemic medication (other than metformin) within the 90 days prior to screening.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes

Contacts and locations

Locations

  • Accellacare - DuPage

    Lombard, Illinois, 60148, United States

  • Accellacare - Mt Pleasant

    Mt. Pleasant, South Carolina, 29464, United States

  • Accellacare - Winston-Salem

    Winston-Salem, North Carolina, 27103, United States

  • Accellacare, US Inc., d/b/a Accellacare of Knoxville

    Jefferson City, Tennessee, 37760, United States

  • Affiliated Hospital of Jiangsu University

    Zhenjiang, Jiangsu, 212000, China

  • Albuquerque Clinical Trials, Inc.

    Albuquerque, New Mexico, 87102, United States

  • Alliance Research Institute - Canoga Park

    Canoga Park, California, 91304, United States

  • Alliance for Multispecialty Research, LLC

    Norman, Oklahoma, 73069, United States

  • Ark Clinical Research

    Long Beach, California, 90815, United States

  • CMR of Greater New Haven, LLC

    Hamden, Connecticut, 06517, United States

  • CRS Clinical Research Services Mannheim

    Mannheim, Baden-Wurttemberg, 68167, Germany

  • Cardiolink Clin Trials

    Monterrey, Nuevo León, 64060, Mexico

  • CenterMed Lublin NZOZ

    Lublin, Lublin Voivodeship, 20-044, Poland

  • Centro Para El Desarrollo de La Medicina Y de Asistencia Medica Especializada S.C.

    Culiacán, Sinaloa, 80230, Mexico

  • Centrum Badań Klinicznych Piotr Napora lekarze sp.p.

    Wroclaw, Lower Silesian Voivodeship, 50-162, Poland

  • Centrum Medyczne "Diabetika"

    Radom, Masovian Voivodeship, 26-600, Poland

  • Centrum Terapii Wspolczesnej J. M. Jasnorzewska Spolka Komandytowo-Akcyjna

    Lodz, Łódź Voivodeship, 90-338, Poland

  • Chang Gung Memorial Hospital at Kaohsiung

    Kaohsiung Niao Sung Dist, Kaohsiung, 83301, Taiwan

  • Clinical Best Solutions

    Lublin, Lublin Voivodeship, 20-011, Poland

  • Clínica García Flores SC

    Monterrey, Nuevo León, 64610, Mexico

  • Collaborative Neuroscience Research, LLC

    Los Alamitos, California, 90720, United States

  • Consano Clinical Research, LLC

    Shavano Park, Texas, 78231, United States

  • Consultorio de Medicina Especilizada del Sector Privado

    Xalapa, Veracruz, 91193, Mexico

  • Cryptex Investigación Clínica S.A. de C.V.

    Cuauhtémoc, Ciudad de México, Mexico City, 06100, Mexico

  • Diabetes Zentrum Wilhelmsburg

    Hamburg, 21109, Germany

  • Diabetes- und Stoffwechselpraxis Bochum

    Bochum, North Rhine-Westphalia, 44869, Germany

  • Diabetologische Schwerpunktpraxis Dr. Staudenmeyer & Dr. Schiwietz

    Lingen, Lower Saxony, 49808, Germany

  • Ekamed

    Lublin, Lublin Voivodeship, 20-718, Poland

  • Elite Clinical Trials

    Rexburg, Idaho, 83440, United States

  • Essential Medical Research

    Tulsa, Oklahoma, 74137, United States

  • First Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, 650032, China

  • Fu Jen Catholic University Hospital

    New Taipei City, 24352, Taiwan

  • Fundación Cardiovascular de Aguascalientes A.C.

    Aguascalientes, 20230, Mexico

  • Grupo Ollin Care

    Pachuca, Hidalgo, 42000, Mexico

  • Hospital Angeles Xalapa

    Xalapa, Veracruz, 91193, Mexico

  • InnoDiab Forschung Gmbh

    Essen, North Rhine-Westphalia, 45136, Germany

  • Institut für Diabetesforschung GmbH Münster

    Münster, North Rhine-Westphalia, 48145, Germany

  • Institute of Endocrinology Diabetes, Health & Hormone

    Stockbridge, Georgia, 30281, United States

  • Instituto Jalisciense de Investigacion en Diabetes y Obesidad

    Guadalajara, Jalisco, 44600, Mexico

  • Instituto de Diabetes, Obesidad y Nutricion

    Cuernavaca, Morelos, 62250, Mexico

  • Jinan Central Hospital

    Jinan, Shandong, 250013, China

  • Juno Research

    Houston, Texas, 77040, United States

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, 807, Taiwan

  • Kaohsiung Veterans General Hospital

    Kaohsiung City, 81362, Taiwan

  • Lahoja. Asociacion Para La Investigacion Y La Farmacovigilancia

    Durango, 34000, Mexico

  • Medizentrum Essen Borbeck

    Essen, North Rhine-Westphalia, 45355, Germany

  • Medyczne Centrum Diabetologiczno Endokrynologiczno Metaboliczne DIAB-ENDO-MET

    Krakow, Lesser Poland Voivodeship, 31-261, Poland

  • NZOZ Centrum Medyczne KERmed

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-231, Poland

  • Nanjing First Hospital

    Nanjing, Jiangsu, 210006, China

  • National Cheng Kung University Hospital

    Tainan, 704, Taiwan

  • National Taiwan University Hospital

    Taipei, 10002, Taiwan

  • Praxis Dr. Veronika Wenzl-Bauer

    Rehlingen, Saarland, 66780, Germany

  • ProcliniQ Investigación Clínica SA de CV

    Mexico City, Mexico City, 14050, Mexico

  • RED-Institut GmbH

    Oldenburg in Holstein, Schleswig-Holstein, 23758, Germany

  • Samodzielny Publiczny Szpital Kliniczny nr 1 SUM

    Zabrze, Silesian Voivodeship, 41-800, Poland

  • Servicios Integrales Nova de Monterrey S.A. de C.V.

    San Nicolás de los Garza, Nuevo León, 66450, Mexico

  • Shanghai Sixth People's Hospital

    Shanghai, Shanghai Municipality, China

  • Specderm Poznanska

    Bialystok, Podlaskie Voivodeship, 15-375, Poland

  • St. Vincent Healthcare

    Billings, Montana, 59101, United States

  • Taichung Veterans General Hospital

    Taichung, 407, Taiwan

  • Taipei Veterans General Hospital

    Taipei, 11217, Taiwan

  • Tandem Clinical Research

    Marrero, Louisiana, 70072, United States

  • The First Affiliated Hospital of Nanyang Medical College

    Nanyang, Henan, 473007, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, 215006, China

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, 325000, China

  • The Fourth Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, 150001, China

  • The Second Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, 210011, China

  • The Second Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, 450014, China

  • The Second People's Hospital of Hefei

    Hefei, Anhui, 230011, China

  • Velocity Clinical Research, Dallas

    Dallas, Texas, 75230, United States

  • Wolverine Clinical Trials

    Santa Ana, California, 92706, United States

  • Zdrowie Osteo-Medic

    Bialystok, Podlaskie Voivodeship, 15-351, Poland

  • Zentrum fur klinische Forschung - Köln

    Cologne, North Rhine-Westphalia, 51069, Germany

  • Zentrum für klinische Studien

    Saint Ingbert, Saarland, 66386, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.